CC-93269

Overview

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

SparkCures ID 311
Developed By Celgene Corporation
Generic Name CC-93269
Treatment Classifications
Treatment Targets

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.